Ulrich Theinel has been appointed chief medical officer of Finch Therapeutics. Before joining the Somerville, MA, microbiome therapeutics developer, Theinel held leadership positions at Novelion Therapeutics, Eleven Biotherapeutics, ImmunoGen, Domantis, and Transkaryotic Therapies. Finch is currently in mid-stage clinical studies testing its microbial therapy as a treatment for Clostridium difficile infection. In other moves, Finch appointed Gregory Perry to serve as chief financial officer.
